Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cutia Therapeutics's enterprise value is HK$-2.2 Mil.
Cutia Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-279.5 Mil. Therefore, Cutia Therapeutics's EV-to-EBITDA for today is 0.01.
The historical rank and industry rank for Cutia Therapeutics's EV-to-EBITDA or its related term are showing as below:
HKSE:02487'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.81 Med: -3.02 Max: 0.09
Current: 0.01
During the past 6 years, the highest EV-to-EBITDA of Cutia Therapeutics was 0.09. The lowest was -13.81. And the median was -3.02.
HKSE:02487's EV-to-EBITDA is ranked better than 95.81% of 430
companies
in the Biotechnology industry
Industry Median: 13.015
vs HKSE:02487: 0.01
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cutia Therapeutics's PE Ratio (TTM) for today is calculated as:
Cutia Therapeutics's share price for today is HK$1.125.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cutia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-0.870.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cutia Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02487 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Cutia Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cutia Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cutia Therapeutics's EV-to-EBITDA falls into.
Cutia Therapeutics's current Enterprise Value is HK$-2.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cutia Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-279.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cutia Therapeutics (HKSE:02487) has a EV-to-EBITDA of 0.01 as of Sep. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cutia Therapeutics. According to the industry distribution chart, Cutia Therapeutics ranks #18 out of 430 companies in the Biotechnology industry, placing it in the top 4.2%.
Is Cutia Therapeutics' EV-to-EBITDA too high?
Cutia Therapeutics' current EV-to-EBITDA is 0.01. The Biotechnology industry median EV-to-EBITDA is 13.02. Cutia Therapeutics' value of 0.01 is 99.9% below this industry median. Based on the distribution chart, Cutia Therapeutics ranks #18 out of 430 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cutia Therapeutics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cutia Therapeutics' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cutia Therapeutics ranks #18 out of 430 companies for EV-to-EBITDA. This places Cutia Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.02. Cutia Therapeutics' value of 0.01 is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 430 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cutia Therapeutics's current EV-to-EBITDA of 0.01 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cutia Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cutia Therapeutics's current EV-to-EBITDA is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cutia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cutia Therapeutics (HKSE:02487) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.87, compared to a current price of HK$1.13 — trading 93.3% below its estimated fair value. The current EV-to-EBITDA is 0.01 and 99.9% below the Biotechnology industry median of 13.02. Cutia Therapeutics' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cutia Therapeutics (HKSE:02487), the current EV-to-EBITDA is 0.01 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cutia Therapeutics (HKSE:02487) Overvalued in 2026?
Based on GuruFocus' analysis, Cutia Therapeutics stock appears to be undervalued.
The current stock price of HK$1.13 is trading 93.3% below its estimated GF Value™ of HK$16.87.
GuruFocus considers Cutia Therapeutics to be Possible Value Trap.
Key valuation signals for HKSE:02487:
EV-to-EBITDA: 0.01
GF Value™: HK$16.87 vs. price of HK$1.13 (93.3% below fair value)
Industry Position: 99.9% below the Biotechnology median (#18 of 430)
No single metric tells the full story. See the HKSE:02487 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cutia Therapeutics is an investment holding company. The Company and its subsidiaries are principally engaged in developing inventive and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. It has a proprietary CATAME technology platform, which includes: Colloidal-Emulsification-Active Encapsulation (CEAE) platform, Aerosol (ARS) platform, Transdermal Delivery (TDD) platform, Actives & Formulation Evaluation (AFE) platform, Micro/Nano-Particulates & Self-Assembly (MiSA) platform, and Ex vivo & Efficacy Evaluation (EVEE) platform. It enables the development of a wide range of product dosage forms and the relevant formulation technology.
39GF Score
Get the complete analysis for HKSE:02487
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02487 has been successfully added to your 
